Biopharma Moves Towards Holistic Alzheimer’s Care After Key Drug Approvals

The Rising Alzheimer's Disease has Led Biopharma to Enter a Holistic Treatment Era

The start to look up for

In the last two years, 2023 and 2024, the treatment for the first-ever disease, Alzheimer's, received approval, which was introduced by Eisai and Biogen (for Leqembi) and Eli Lilly’s Kisunla. This initiative made a space for rethinking introducing holistic treatments for certain or severe diseases that have limited treatment options. M&A deals rose from $2 billion in 2022 to $18 billion in 2024. Though the limitation of the anti-amyloid antibodies is gaining more money towards biopharma’s valuable efforts to bring new treatments that identify alzheimer’s severity.

Companies such as Bristol Myers Squibb, Acadia, Lundbeck, and Otsuka Pharmaceuticals are jumping into new approaches for the traditional/previous treatments in the struggle against alzheimer’s mood impairments and cognition. These companies discovered the need for a continuum of care for Alzheimer patients, aiming to preventable molecules or steady progress of the therapies and diseases affecting a patient's experience. Eli Lilly, Eisai, and Biogen were the start that the whole biopharma community needed, and were further viewed as an encouragement to innovate new treatments for serious diseases such as Alzheimer's.

About Leqembi and Kisunla

Kisunla and Leqembi learned to have a limited efficacy and were afflicted by concern about amyloid-related imaging abnormalities (ARIA). Other than these, the drug received an approval to treat patients with mild-to-moderate Alzheimer’s disease. Most of the patient’s health felt progress. Over 55 million and more people were found with dementia globally in 2020, according to alzheimer’s Disease International. The number is assumed to rise by 78 million by 2030. The biopharma has taken responsibility and has been making efforts to discover new treatments, which might control the numbers to meet the positive possibilities. Drugs come with challenges and offer various solutions, either relieving symptoms or revealing the need to discover more potential breakthroughs for a drug to be officially recognized as an effective solution in the global health market.

Views and Statements

CEO of Acadia Pharmaceuticals, Catherine Owen Adams, who is developing a treatment for Alzheimer’s disease psychosis, said, “We all are aware of how difficult neurodegenerative diseases are. So many patients are affected by alzheimers globally. I think this is the right time to at least begin to mitigate a few of these symptoms. The mood and cognitive challenges related to Alzheimer's are the main reason for patients being admitted for long-term care.”